NIFTY50: 25,800.60, 286.30 (1.12%). SENSEX: 83,980.83, 959.08 (1.16%)
ISIN: INE858L01010PharmaceuticalsSmall Cap

CONCORD
Concord Drugs Limited

68.87-0.92(-1.32%)
BSE20-Nov-202604:01:17 PM
Day’s Open
68.00
Prev Day Close
69.79
Market Cap (in Cr)
91.95
ATP
68.32
Volume
1,229
Avg. 3month Vol
4,636
Lower Circuit Limit
54.81
Upper Circuit Limit
82.21
20 Nov 2026 04:01:17 PM
 
 
  • 68.87
  • 68.00
  • 1 Day Low/High
  • 69.00
  • 20-Nov-2026
  • 20-Nov-2026

Concord Drugs Share - Key Metrics

19-Nov-2026, 6:30 PM
Market Cap(₹ Cr)91
Face Value10.00
Beta 1Yr0.49
Shares OS (in cr)1.32
Earnings Per Share (TTM)2.31
Book Value Per Share (TTM)38.50
Dividend0.00

Concord Drugs Share Price - Historic Returns

20-Nov-2026, 10:31 AM
1 Week-3.92%NA
NA
1 Month+3.15%NA
NA
3 Month-3.01%NA
NA
6 Month-14.71%NA
NA
1 Year-15.34%-11.14%
-4.20%
3 Year+103.76%+17.80%
85.96%
5 Year+136.67%+67.56%
69.11%
YTD-16.50%-9.12%
-7.38%

Concord Drugs Share - Growth Metrics

Sales114.17%14.77%
EBITDA57.14%-0.44%
PAT434.55%1.98%
EPS298.28%-8.95%
Sales122.78%13.92%
EBITDA66.35%-0.78%
PAT490.00%5.39%
EPS332.08%-6.29%
*TTM: ending
SEP '26
*Annual: ending
MAR '26

Concord Drugs Ltd. Share - Volume Analysis

20-Nov-2026, 6:25 PM
Today
1.23K
Yesterday
6.75K
5.94K
88 %
5 Day Avg
4.28K
3.70K
86.37 %
30 Day Avg
3.87K
3.07K
79.25 %
Total VolDelivery Volume

Concord Drugs Share - Valuation Summary

PE Ratio32.0787.79
P/Bv1.871.98
EV/EBITDA16.2723.34
EV/Sales1.211.35
MCAP/Sales0.981.18
PE Ratio32.0787.79
P/Bv1.871.98
EV/EBITDA16.2723.34
EV/Sales1.211.35
MCAP/Sales0.981.18
*TTM ending
SEP '26
*Annual: ending
MAR '26

Concord Drugs Share - Seasonality Returns Analysis

Stock Scan
PeriodJanFebMarAprMayJunJulyAugSeptOctNovDec
Monthly Avg
2019
< -10
-10 to -5
-5 to 0
0 to 5
5 to 10
> 10

Concord Drugs Share Price - Technical Summary

19-Nov-2026
Pivot Level
R171.97
Pivot
69.81
S167.63
R274.15
S265.47
R376.31
S363.29
Technical Moving Average
0
8
 Bullish
Bearish 
5
70.90
1.59% abv LTP
10
70.70
1.30% abv LTP
12
70.60
1.16% abv LTP
20
70.40
0.87% abv LTP
26
70.50
1.02% abv LTP
50
71.60
2.59% abv LTP
100
73.20
4.89% abv LTP
200
73.00
4.60% abv LTP
5
71.00
1.73% abv LTP
10
71.50
2.45% abv LTP
20
68.90
1.28% blw LTP
30
69.20
0.85% blw LTP
50
72.40
3.74% abv LTP
100
73.20
4.89% abv LTP
150
75.80
8.61% abv LTP
200
76.00
8.90% abv LTP
Technical Indicators
4
3
 Bullish
Bearish 
Relative Strength Index47.93
RSI is mid-range
Money Flow Index39.07
MFI is mid-range
MACD0.08
MACD above Signal and Center
MACD Signal-0.31
MACD above Signal and Center
Average True Range4.21
Average Directional Index21.73
Rate of Change (21)4.52
Rate of Change (125)-12.76
Day Commodity Channel Index11.20
William-53.00
-53.04 William
Stochastic Oscillator61.72
Stochastic Oscillator %D67.76
Stochastic RSI67.07
Stochastic RSI %D74.56
Awesome Oscillator1.01
Ultimate Oscillator35.97
Momentum Oscillator-1.74

Concord Drugs Ltd. Share Price - Key Fundamentals

Financial Analysis
FY End
Trend
MAR '26
MAR '25
MAR '24
MAR '23
MAR '22
Net Sales
Growth %
78.74
+74.05%
45.24
+0.71%
44.92
-13.75%
52.08
-11.67%
58.96
NA
Total Expenditure
Growth %
% of Sales
74.22
+80.54%
+94.26%
41.11
+0.51%
+90.87%
40.90
-13.89%
+91.05%
47.50
-11.02%
+91.21%
53.38
NA
+90.54%
EBITDA(Operating Profit)
Growth %
Margin %
4.52
+9.44%
+5.74%
4.13
+2.74%
+9.13%
4.02
-12.23%
+8.95%
4.58
-17.92%
+8.79%
5.58
NA
+9.46%
Depreciation
1.37
1.43
1.56
1.63
1.76
EBIT
Growth %
Margin %
3.15
+16.67%
+4.00%
2.70
+9.76%
+5.97%
2.46
-16.61%
+5.48%
2.95
-22.77%
+5.66%
3.82
NA
+6.48%
Interest
% of EBIT
1.71
+54.29%
2.03
+75.19%
1.87
+76.02%
1.71
+57.97%
1.68
+43.98%
Other income
0.03
0.01
0.01
0.01
0.10
Minority int (before tax)
-
-
-
-
-
Profit Before Tax
Growth %
Margin %
1.47
+116.18%
+1.87%
0.68
+13.33%
+1.50%
0.60
-52.00%
+1.34%
1.25
-44.20%
+2.40%
2.24
NA
+3.80%
Total Tax
Tax Rate %
0.42
+28.57%
0.35
+51.47%
0.16
+26.67%
0.26
+20.80%
0.65
+29.02%
Profit After Tax
Growth %
Margin %
1.05
+218.18%
+1.33%
0.33
-25.00%
+0.73%
0.44
-55.56%
+0.98%
0.99
-37.74%
+1.90%
1.59
NA
+2.70%
Minority int (after tax)
-
-
-
-
-
Profit/Loss of Associate Company
-
-
-
-
-
PAT after Minority int & P/L Asso.Co.
1.05
0.33
0.44
0.99
1.59
Extraordinary Items
-
-
-
-
-
Adj Profit After Tax
Growth %
Margin %
1.05
+218.18%
+1.33%
0.33
-25.00%
+0.73%
0.44
-55.56%
+0.98%
0.99
-37.74%
+1.90%
1.59
NA
+2.70%
EPS (Adj)
0.80
0.34
0.47
1.06
1.82
Dividend Per Share Adj.(Rs)
-
-
-
-
-
Book Value (Adj) (Unit Curr.)
35.43
34.11
33.82
33.43
32.44
FY End
Trend
MAR '26
MAR '25
MAR '24
MAR '23
MAR '22
Liabilities
Total Shareholders Funds
48.52
34.11
33.82
31.70
28.36
Minority int
-
-
-
-
-
Total Debt
14.51
19.24
17.52
16.96
16.43
Policy Holders Fund
-
-
-
-
-
Other Liabilities
2.87
2.91
2.86
2.47
2.09
Total Liabilities
65.90
56.26
54.20
51.13
46.88
Assets
Net Block
11.58
12.21
11.67
12.92
13.97
Lease Adjustment
-
-
-
-
-
Capital Work in Progress
2.43
2.00
1.63
0.92
0.55
Investments
0.78
0.80
0.84
0.89
-
Loans
-
-
-
-
-
Inventories
25.52
25.27
22.92
20.06
17.49
Sundry Debtors
24.38
13.60
12.73
15.81
22.86
Cash and Bank
0.75
0.23
0.18
0.10
0.07
Loans and Advances
2.67
1.66
1.69
7.48
1.48
Total Current Assets
53.32
40.76
37.52
43.45
41.90
Less : Current Liabilities and Provisions
Current Liabilities
7.95
8.05
3.91
6.18
8.24
Provisions
0.41
0.21
0.22
0.38
0.67
Total Current Liabilities
8.36
8.26
4.13
6.56
8.91
Net Current Assets
44.96
32.50
33.39
36.89
32.99
Miscellaneous Exp. not written off
-
-
-
-
-
Deferred Tax Assets
-
-
-
-
-
Deferred Tax Liability
0.63
0.63
0.47
0.54
0.66
Net Deferred Tax
-0.63
-0.63
-0.47
-0.54
-0.66
Other Assets
6.78
9.38
7.14
0.05
0.03
Total Assets
65.90
56.26
54.20
51.13
46.88
FY End
Trend
MAR '26MAR '25MAR '24MAR '23MAR '22
Cash and Cash Equivalents at Beginning of the year
-
-
-
-
-
Net Cash from Operating Activities
-6
4
1
2
1
Net Cash Used in Investing Activities
-1
-2
-1
-2
-2
Net Cash Used in Financing Activities
7
-1
-
1
2
Net inc/(Dec) in Cash and Cash Equivalent
-
-
-
-
-
Cash and Cash Equivalents at End of the year
-
-
-
-
-
Other Bank Balance
-
-
-
-
-
Total Cash & Bank
1
-
-
-
-

FY End
Sales Growth
EBITDA Growth
EBIT Growth
Profit Before Tax Growth
Profit After Tax Growth
Adj Profit After Tax Growth
Sales 3 yr CAGR
EBITDA 3 yr CAGR
Adj Profit After Tax 3 yr CAGR
MAR '26
+74.05%
+9.44%
+16.67%
+116.18%
+218.18%
+218.18%
+14.77%
-0.44%
+1.98%
MAR '25
+0.71%
+2.74%
+9.76%
+13.33%
-25.00%
-25.00%
-8.45%
-9.54%
-40.79%
MAR '24
-13.75%
-12.23%
-16.61%
-52.00%
-55.56%
-55.56%
-
-
-
MAR '23
-11.67%
-17.92%
-22.77%
-44.20%
-37.74%
-37.74%
-
-
-
MAR '22
NA
NA
NA
NA
NA
NA
-
-
-

FY End
EBITDA
EBIT
Profit Before Tax
Profit After Tax
Adj Profit After Tax
MAR '26
+5.74%
+4.00%
+1.87%
+1.33%
+1.33%
MAR '25
+9.13%
+5.97%
+1.50%
+0.73%
+0.73%
MAR '24
+8.95%
+5.48%
+1.34%
+0.98%
+0.98%
MAR '23
+8.79%
+5.66%
+2.40%
+1.90%
+1.90%
MAR '22
+9.46%
+6.48%
+3.80%
+2.70%
+2.70%

FY End
Debt Equity Ratio
Long Term Debt Equity Ratio
Interest Coverage Ratio
MAR '26
0.41
0.05
+54.29%
MAR '25
0.54
0.04
+75.19%
MAR '24
0.53
0.04
+76.02%
MAR '23
0.56
0.06
+57.97%
MAR '22
0.58
0.06
+43.98%

FY End
Return on Capital Employed
Return on Networth
MAR '26
+5.22%
+2.57%
MAR '25
+4.94%
+1.00%
MAR '24
+4.75%
+1.43%
MAR '23
+6.04%
+3.30%
MAR '22
+8.36%
+5.61%

FY End
Fixed Asset Turnover
Inventory Turnover
Debtors Turnover
MAR '26
1.95
3.10
4.15
MAR '25
1.16
1.88
3.44
MAR '24
1.19
2.09
3.15
MAR '23
1.39
2.77
2.69
MAR '22
1.59
3.37
2.58

FY END
Price to Earnings (PE)
Price to Book Value (PBV)
EV to EBITDA
EV to Sales
TTM
32.07
1.87
16.27
1.21
2026
87.79
1.98
23.34
1.35
2025
91.41
0.91
12.08
1.11
2024
74.83
1.04
12.96
1.17
2023
25.90
0.82
9.26
0.78

FY End
EPS
DPS
Book Value
Face Value
MAR '26
0.80
-
35.43
10.00
MAR '25
0.34
-
34.11
10.00
MAR '24
0.47
-
33.82
10.00
MAR '23
1.06
-
33.43
10.00
MAR '22
1.82
-
32.44
10.00
Download
FY End20262025202420232022
Annual Reports
Investor Presentation
Earnings Call

Concord Drugs Share - SWOT Analysis

  • Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
  • Companies with high TTM EPS Growth
  • Growth Stars: Strongest Annual EPS Performers
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
  • Companies with Low Debt
  • Book Value per share Improving for last 2 years
  • Companies with Zero Promoter Pledge
  • Declining Revenue every quarter for the past 2 quarters
  • Weak Momentum: Price below Short, Medium and Long Term Averages
  • Increasing Trend in Non-Core Income
Data not available
Data not available

Concord Drugs Ltd. Share - Corporate Actions/News

Live News

No Data available

Concord Drugs Share - Deals Summary

Reported on
Client Name/Category
Mode
Average Price
ActionNo of shares (% of total)
02-Dec-25
S Koni Reddy
NA
5,00,000  (3.80%)
02-Dec-25
S Nagi Reddy
NA
5,00,000  (3.80%)
02-Dec-25
S Manoj Kumar Reddy
NA
5,00,000  (3.80%)
24-Nov-25
S Koni Reddy
9.07
5,50,000  (4.17%)
24-Nov-25
S Manoj Kumar reddy
36.30
1,50,000  (1.14%)
24-Nov-25
S Nagi Reddy
36.30
2,00,000  (1.52%)
Reported on
Client Name/Category
Average Price
ActionNo of shares (% of total)
04-Jul-25
PRADEEP KUMAR JAIN
54.48
69,944  (0.53%)
03-Jul-25
GANGA DEVI LOYA
53.25
51,655  (0.39%)
03-Jul-25
PRADEEP KUMAR JAIN
53.21
1,49,164  (1.13%)
03-Jul-25
GANGA DEVI LOYA
53.90
11,555  (0.09%)
30-Jun-25
GANGA DEVI LOYA
38.66
51,571  (0.39%)
15-Jan-24
LAKSHMI PRASANNA PALLETI
44.63
51,994  (0.39%)

 About Company

About Concord Drugs Limited

Key Brands
  • Concord Drugs
Industry
Pharm-Ind-BD&For
Contact Information
Tel. No.
91-40-24036379
Fax No.
null
Company website
http://www.concorddrugs.in
Details
BSE
CONCORD
NSE
CONCORD
Series
EQ
ISIN
INE858L01010
Executive Summary
Chairman / Executive Director / M D / Promoter
S Nagi Reddy
ED / WTD / CFO / Promoter
Koni Reddy
WTD & Executive Director
S. Manoj Kumar Reddy
Independent Non Exe. Director
K Ramchandra Reddy
Independent Non Exe. Director
Summela Kasu

Understanding Sections

Insider Trading and SAST
Back to Insider Trading and SAST
Insider trading refers to trading in a shares by someone who has access to non-public, material information about that stock that can affect the stock’s price. SAST (Substantial Acquisition of Shares and Takeovers) refers to trades which involve high volume resulting in the acquirer acquiring substantial number of shares and voting rights in the target company (Substantial Acquisition of Shares) or taking over the control of the target company (Takeovers)
Seasonality Analysis
Back to Seasonality Analysis
Seasonality Analysis shows how a stock / index performs during a month across years based on various parameters like average returns, number of positive years, number of negative years etc. For indices you can also check the stocks which perform better/worse during a month across the years.